{"entity":{"id":"idea-tr1-tumour-board-trial-line-item","kind":"idea","name":"A mandatory trial line in every tumour board recommendation","aka":[],"tldr":"Every time a team of specialists meets to plan a patient's treatment, they would have to record whether a trial exists for that patient and, if so, why it was or was not offered.","summary":"Multidisciplinary tumour boards and molecular tumour boards add a required structured field to their recommendation: matched trials considered (with identifiers), offered yes/no, and reason if not. A trial coordinator pre-populates the field from a matching tool before the meeting. The field is auditable and the offer rate reported quarterly by service.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Trials enrol too few, too slowly): Unger et al., Systematic review of barriers to cancer trial participation (JNCI 2019)","url":"https://doi.org/10.1093/jnci/djy221"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","royal-marsden","gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Making trial consideration a documented step raises the trial offer rate from the typical single digits to over 20 percent of board-discussed patients within a year, and enrolment rises in proportion.","rationale":"Checklists change behaviour where the omission is habitual rather than deliberate. Surgical safety checklists and the 'sepsis six' work through the same mechanism. Tumour boards already have the structure; only the field is missing.","test":"Before-after with contemporaneous control services in two cancer centres; outcome is documented trial offers and enrolments per 100 board discussions.","maturity":"speculative","actor":"clinic","cost":"small","horizonYears":1},"route":"/ideas/idea-tr1-tumour-board-trial-line-item/","neighbours":{"technology":[{"id":"ai-trial-matching","kind":"technology","name":"AI trial matching & clinical decision support","route":"/technologies/ai-trial-matching/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/"}],"bottleneck":[{"id":"b-trial-enrolment","kind":"bottleneck","name":"Trials enrol too few, too slowly","route":"/bottlenecks/b-trial-enrolment/"}]}}